Production (Stage)
Aldeyra Therapeutics, Inc.
ALDX
$2.22
-$0.03-1.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.69M | 11.89M | 11.74M | 10.64M | 10.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.15M | 60.12M | 49.64M | 43.05M | 35.38M |
| Operating Income | -61.15M | -60.12M | -49.64M | -43.05M | -35.38M |
| Income Before Tax | -57.70M | -55.85M | -44.80M | -37.87M | -30.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.70 | -55.85 | -44.80 | -37.87 | -30.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.70M | -55.85M | -44.80M | -37.87M | -30.01M |
| EBIT | -61.15M | -60.12M | -49.64M | -43.05M | -35.38M |
| EBITDA | -60.90M | -59.87M | -49.39M | -42.80M | -35.13M |
| EPS Basic | -0.97 | -0.94 | -0.75 | -0.64 | -0.51 |
| Normalized Basic EPS | -0.61 | -0.59 | -0.47 | -0.40 | -0.32 |
| EPS Diluted | -0.97 | -0.94 | -0.75 | -0.64 | -0.51 |
| Normalized Diluted EPS | -0.61 | -0.59 | -0.47 | -0.40 | -0.32 |
| Average Basic Shares Outstanding | 238.41M | 237.94M | 237.56M | 237.02M | 236.39M |
| Average Diluted Shares Outstanding | 238.41M | 237.94M | 237.56M | 237.02M | 236.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |